HyperRAB®

Rabies vaccine and HyperRAB®S/D should be given to all persons suspected of exposure to rabies with one exception: Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRAB®S/D should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given.

Recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the U.S. Public Health Service Advisory Committee on Immunization Practices (ACIP).

Every exposure to possible rabies infection must be individually evaluated;  the factors, as detailed in the PI, should be considered before specific anti-rabies treatment is initiated.

For indications, dosing and other information, please refer to the prescribing information.

HyperRAB® ‐ Grifols

Size:
2 mL vial
NDC #:
13533-0618-02
Download:
PI
Size:
10 mL vial
NDC #:
13533-0618-10
Download:
PI